Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884308 | 0.68 | CHRNB4 (0.39) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL3080293 | 0.64 | NOS3 (0.47) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL18391503 | 0.63 | CHRNB4 (0.31) | CHRNB4CHRNA3 | |
| SCHEMBL22023761 | 0.63 | CHRNB4 (0.34) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL2503027 | 0.62 | TYMP (0.31) | — | |
| SCHEMBL4771296 | 0.61 | CHRNB4 (0.41) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL12533295 | 0.58 | CHRNB4 (0.46) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL9322982 | 0.56 | CHRNB4 (0.45) | CHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL1697263 | 0.55 | CHRNB4 (0.44) | CHRNB4CHRNA3 | |
| SCHEMBL3141751 | 0.55 | CHRNB4 (0.44) | CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-10-06 | — | — | US | claimed |
| WO-2010077740-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2010077740-A2 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYTOKINE PHARMASCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245156-A1 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | DDX5, SAMHD1, EIF2AK2 | CHRNB4 4595/4885CHRNA3 4552/4885ALDH1A1 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.